KRAS and colorectal carcinoma: Together, these data suggest that in CRC cells with KRASG12/G13 mutation-driven acquired resistance, a translationally primed state overcomes codon bias and facilitates expression of mutant KRAS at levels sufficient to potentiate resistance.